All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

CAR T-cell therapy or bispecific T-cell engagers for the treatment of patients with MM?

Multiple Myeloma Hub Co-Chair María-Victoria Mateos, University Hospital of Salamanca, Salamanca, ES, provided the Multiple Myeloma Hub with updates from this year's virtual American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Annual Congress. We asked, CAR T-cell therapy or bispecific T-cell engagers for the treatment of patients with MM?

CAR T-cell therapy or bispecific T-cell engagers for the treatment of patients with MM?

Significant improvements in both the diagnosis and treatment of MM have been observed in recent years. Despite this, MM remains an incurable disease and patients eventually relapse or become refractory to treatment. CAR T-cell therapy and bispecific T-cell engager monoclonal antibodies have demonstrated promising results in this setting. Here, María-Victoria Mateos outlines the major factors for consideration when choosing a patient's treatment course with such agents.

Share: